1. Home
  2. NIE vs DBVT Comparison

NIE vs DBVT Comparison

Compare NIE & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

N/A

Current Price

$21.23

Market Cap

658.4M

Sector

Finance

ML Signal

N/A

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

N/A

Current Price

$9.02

Market Cap

692.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NIE
DBVT
Founded
2007
2002
Country
United States
France
Employees
N/A
90
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
658.4M
692.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NIE
DBVT
Price
$21.23
$9.02
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $36.51
AVG Volume (30 Days)
68.1K
★ 300.2K
Earning Date
01-01-0001
10-28-2026
Dividend Yield
★ 9.04%
N/A
EPS Growth
N/A
★ 10.26
EPS
★ N/A
N/A
Revenue
N/A
★ $5,636,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,837.59
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 35.77
52 Week Low
$22.16
$8.63
52 Week High
$27.24
$26.19

Technical Indicators

Market Signals
Indicator
NIE
DBVT
Relative Strength Index (RSI) 19.32 37.71
Support Level N/A $8.78
Resistance Level $26.93 $12.41
Average True Range (ATR) 0.50 0.76
MACD -0.18 -0.12
Stochastic Oscillator 0.95 0.97

Price Performance

Historical Comparison
NIE
DBVT

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: